Recursion Pharmaceuticals (RXRX) Non-Current Assets (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Non-Current Assets came in at $630.0 million in Q1 2026, down 12.64% YoY from $721.1 million in Q1 2025, and down 4.74% on a QoQ basis from $661.3 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Non-Current Assets (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Non-Current Assets data on file, last reported at $630.0 million in Q1 2026.
- Quarterly Non-Current Assets fell 12.64% year-over-year to $630.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 billion (up 37.25% YoY) and the FY2025 annual result came in at $661.3 million, down 9.95% from the prior year.
- Non-Current Assets declined to $630.0 million in Q1 2026, from $661.3 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $734.3 million in Q4 2024 to a low of $114.9 million in Q1 2022.
- A 5-year average of $363.3 million and a median of $235.7 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets jumped 240.66% — and 2026, when it dropped 12.64%.
- Tracing RXRX's Non-Current Assets over 5 years: stood at $131.5 million in 2022, then jumped by 63.96% to $215.6 million in 2023, then jumped by 240.66% to $734.3 million in 2024, then slipped by 9.95% to $661.3 million in 2025, then declined by 4.74% to $630.0 million in 2026.
- The last three Non-Current Assets figures came in at $630.0 million (Q1 2026), $661.3 million (Q4 2025), and $685.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 609.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 609.21 Mn |
| Mar 31, 2026 | 629.97 Mn |
| Dec 31, 2025 | 661.29 Mn |
| Sep 30, 2025 | 685.42 Mn |
| Jun 30, 2025 | 715.20 Mn |
| Mar 31, 2025 | 721.09 Mn |
| Dec 31, 2024 | 734.33 Mn |
| Sep 30, 2024 | 252.33 Mn |
| Jun 30, 2024 | 253.49 Mn |
| Mar 31, 2024 | 214.23 Mn |
| Dec 31, 2023 | 215.56 Mn |
| Sep 30, 2023 | 220.30 Mn |
| Jun 30, 2023 | 235.68 Mn |
| Mar 31, 2023 | 135.24 Mn |
| Dec 31, 2022 | 131.47 Mn |
| Sep 30, 2022 | 129.92 Mn |
| Jun 30, 2022 | 126.52 Mn |
| Mar 31, 2022 | 114.86 Mn |
| Dec 31, 2021 | 75.63 Mn |
| Sep 30, 2021 | 57.74 Mn |